Agios Pharmaceuticals (AGIO) Net Income towards Common Stockholders (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 14 years of Net Income towards Common Stockholders data on file, last reported at -$143.2 million in Q2 2026.

• Quarterly Net Income towards Common Stockholders fell 8.53% year-over-year to -$143.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$502.5 million (down 182.65% YoY) and the FY2025 annual result came in at -$412.8 million, down 161.27% from the prior year.
• Net Income towards Common Stockholders rose to -$143.2 million in Q2 2026, from -$147.8 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $947.9 million in Q3 2024 to a low of -$147.8 million in Q1 2026.
• A 4-year average of -$33.3 million and a median of -$100.1 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders jumped 1137.97% — and 2025, when it sank 110.91%.
• Tracing AGIO's Net Income towards Common Stockholders over 4 years: stood at -$95.9 million in 2023, then retreated by 0.61% to -$96.5 million in 2024, then dropped by 11.93% to -$108.0 million in 2025, then sank by 32.57% to -$143.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$143.2 million (Q2 2026), -$147.8 million (Q1 2026), and -$108.0 million (Q4 2025), per Business Quant data.